Picture of Eli Lilly and logo

LLY — Eli Lilly and News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

DNA drug developer Seawolf launches with $100 million funding, Sanofi deal

DNA drug developer Seawolf launches with $100 million funding, Sanofi deal 

- Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi SASY.PA worth up to $1.2 billion, as it seeks to develop DNA-based medicines.

  • The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly LLY.N, CRISPR Therapeutics CRSP.BN and others

  • San Diego-based Seawolf and Sanofi will develop treatments for bleeding disorders and other undisclosed conditions

  • Seawolf could get milestone payments and royalties

  • CEO Elizabeth Alcamo told Reuters the agreement includes an upfront payment, though she declined to say how much

  • Seawolf's technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells without using viruses

  • The company says it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack

  • The lead program, which has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis

  • Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028

  • But "we'll probably need to raise some additional capital" to reach that stage, Alcamo said


(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)

((Kamal.Choudhury@thomsonreuters.com;))

Recent news on Eli Lilly and

See all news